Ensemble is pursuing proprietary discovery and development programs in inflammation, oncology (including the BCL-2 family), pain and diabetes, largely focusing on Ensemblins that inhibit protein-protein or protein-peptide interactions.

In addition to its own programs, Ensemble is making rapid progress together with its collaboration partners, Bristol-Myers Squibb and Pfizer against a number of high-value drug targets in multiple therapeutic areas.

[ back to top ]